Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 7;13(5):796-798.
doi: 10.2215/CJN.12871117. Epub 2018 Mar 9.

Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know

Kenar D Jhaveri  1 , Mitchell H Rosner  2
Affiliations

Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know

Kenar D Jhaveri et al. Clin J Am Soc Nephrol. .
No abstract available

Keywords: CAR-T; adaptive cell transfer; chimeric receptor receptor therapy; cytokines; drug nephrotoxicity; onconephrology.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Engineering of Chimeric Antigen Receptor therapy. (Left Panel) T cells are collected via apheresis from the patient, a process that withdraws blood from the body and removes one or more blood components (such as plasma, platelets, or white blood cells). The remaining blood is then returned back into the body. T cells are re-engineered in a laboratory. The T cells are sent to a laboratory or a drug manufacturing facility, where they are genetically engineered to produce chimeric antigen receptors (CARs) on their surface. After this re-engineering, the T cells are known as chimeric antigen receptor T (CAR-T) cells. CARs are proteins that allow the T cells to recognize an antigen on targeted tumor cells. The re-engineered CAR-T cells are then multiplied. The number of the patient’s genetically modified T cells is “expanded” by growing cells in the laboratory until there are many millions of them. These CAR-T cells are frozen, and when there are enough of them, they are sent to the hospital or center where the patient is being treated. At the hospital or treatment center, the CAR-T cells are then infused into the patient. Many patients are given a brief course of one or more chemotherapy agents before they receive the infusion of CAR-T cells. CAR-T cells that have been returned to the patient’s bloodstream multiply in number. (Right panel) Kidney effects of CAR-T cell therapy. CAR-T cell infusion can lead to cytokine release syndrome due predominantly to IL-6 release along with other inflammatory cytokines. AKI results from a combination of hypoperfusion due to third spacing of fluids, hypotension, cytokine-induced cardiomyopathy, and direct inflammatory effects. AKI may be mild and prerenal or severe and due to acute tubular necrosis.
See this image and copyright information in PMC

References

    1. Gross G, Waks T, Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86: 10024–10028, 1989 - PMC - PubMed
    1. Gill S, Maus MV, Porter DL: Chimeric antigen receptor T cell therapy: 25 Years in the making. Blood Rev 30: 157–167, 2016 - PubMed
    1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509–1518, 2013 - PMC - PubMed
    1. Porter DL, Levine BL, Kalos M, Bagg A, June CH: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725–733, 2011 - PMC - PubMed
    1. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN: B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 19: 2048–2060, 2013 - PMC - PubMed

MeSH terms